Los Angeles Capital Management LLC Has $2.34 Million Stake in STERIS plc $STE

Los Angeles Capital Management LLC lowered its position in STERIS plc (NYSE:STE) by 42.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,917 shares of the medical equipment provider’s stock after selling 7,443 shares during the period. Los Angeles Capital Management LLC’s holdings in STERIS were worth $2,342,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Board of the Pension Protection Fund acquired a new position in shares of STERIS in the 4th quarter worth approximately $25,000. Harbor Investment Advisory LLC lifted its position in shares of STERIS by 115.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 60 shares during the period. Activest Wealth Management lifted its position in shares of STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 89 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in shares of STERIS in the 4th quarter worth approximately $28,000. Finally, Geneos Wealth Management Inc. lifted its position in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $270.00 price target on shares of STERIS in a research report on Thursday, May 21st. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday. KeyCorp cut their target price on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $278.00.

STERIS Stock Up 1.1%

Shares of NYSE STE opened at $212.42 on Wednesday. The firm has a market cap of $20.73 billion, a PE ratio of 26.79 and a beta of 0.93. STERIS plc has a 12-month low of $195.14 and a 12-month high of $269.44. The company’s fifty day simple moving average is $216.83 and its 200 day simple moving average is $238.33. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25.

STERIS (NYSE:STE) last released its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the previous year, the company posted $2.74 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, sell-side analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a dividend of $0.63 per share. The ex-dividend date is Monday, June 8th. This represents a $2.52 annualized dividend and a yield of 1.2%. STERIS’s dividend payout ratio is presently 31.78%.

Insider Buying and Selling at STERIS

In other STERIS news, Director Richard C. Breeden sold 1,481 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the transaction, the director owned 38,964 shares in the company, valued at approximately $8,163,347.64. This represents a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel A. Carestio sold 3,054 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total transaction of $655,510.56. Following the transaction, the chief executive officer owned 65,021 shares in the company, valued at approximately $13,956,107.44. The trade was a 4.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 5,909 shares of company stock worth $1,257,083. Corporate insiders own 1.07% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.